<DOC>
	<DOCNO>NCT00890955</DOCNO>
	<brief_summary>Amrubicin show single-agent activity lung cancer . The combination cyclophosphamide anthracyclines study concluded combination tolerable , could give safely , therapeutically useful . This Phase I study evaluate combination cyclophosphamide amrubicin relapse solid tumor define MTD combination US population .</brief_summary>
	<brief_title>Amrubicin + Cyclophosphamide Advanced Solid Organ Malignancies</brief_title>
	<detailed_description>OUTLINE : This multi-center study . This study follow 3+3 design follow dose level : - Dose Level -1 : Amrubicin 20mg/m2 , Cyclophosphamide 500mg/m2 - Dose Level 1 : Amrubicin 25mg/m2 , Cyclophosphamide 500mg/m2 - Dose Level 2 : Amrubicin 30mg/m2 , Cyclophosphamide 500mg/m2 - Dose Level 3 : Amrubicin 35mg/m2 , Cyclophosphamide 500mg/m2 - Dose Level 4 : Amrubicin 40mg/m2 , Cyclophosphamide 500mg/m2 Dose escalation start dose level 1 . Amrubicin give slow IV push infusion approximately 5 minute daily 3 consecutive day start day 1 21 day cycle . Cyclophosphamide give fix dose IV infusion 30-60 minute day 1 21 day cycle ( follow amrubicin ) . ECOG Performance Status : 0-1 Life expectancy : specify Hematopoietic : - Hemoglobin ( Hgb ) &gt; 9 g/dL . - Platelets &gt; 100 K/mm3 - Absolute Neutrophil Count ( ANC ) &gt; 1.5 K/mm3 Hepatic : - Aspartate transaminase ( AST ) ≤ 2.5 x ULN - Alanine transaminase ( ALT ) ≤ 2.5 x ULN - Total bilirubin &lt; 1.5 x ULN Renal : - Calculated creatinine clearance ≥ 60cc/min Cardiovascular : - Left Ventricular Ejection Fraction ( LVEF ) ≥ LLN institution within 60 day prior registration protocol therapy . - No history cardiomyopathy uncontrolled heart arrhythmia . Pulmonary : - No suspected , diffuse idiopathic interstitial lung disease history pulmonary fibrosis .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid organ malignancy refractory currently available therapy effective therapy exists . Must measurable evaluable disease per RECIST evaluate image within 30 day prior registration protocol therapy . Must complete chemotherapy least 28 day prior registration protocol therapy recover acute toxic effect . Prior radiation therapy allow &lt; 25 % bone marrow . Patients must recover acute toxic effect radiation prior registration protocol therapy . Must willing consent blood sample collection SNP analysis . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent least 30 day follow completion protocol therapy . Females childbearing potential must negative pregnancy test within 7 day prior registration protocol therapy . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year . No prior therapy cyclophosphamide anthracyclines . No treatment investigational agent within 28 day prior registration protocol therapy . No suspected , diffuse idiopathic interstitial lung disease history pulmonary fibrosis . No evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol . No symptomatic brain metastasis . Patients treat brain metastasis must steroids must complete radiation least 21 day prior registration protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>